home / stock / cere / cere news

CERE News and Press, Ceres Inc. From 10/19/22

Stock Information
Company Name: Ceres Inc.
Stock Symbol: CERE
Market: NASDAQ
Website: cerevel.com
Menu
CERE CERE Quote CERE Short CERE News CERE Articles CERE Message Board
Get CERE Alerts

News, Short Squeeze, Breakout and More Instantly...
CERE - Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8...
CERE - Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Wells Fargo has initiated Cerevel Theraspeutics Holdings ( NASDAQ: CERE ) with an overweight rating on the potential of its neuroscience pipeline. The firm has a $38 price target (~45% upside based on Friday's close). Analyst Mohit Bansal said while much of the focus o...

CERE - Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20 th Annual ...

CERE - Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Cerevel Therapeutics ( NASDAQ: CERE ) priced its earlier announced private offering of $300M principal amount of 2.50% convertible senior notes due 2027. Initial purchasers granted 13-day option to purchase up to an additional $45M principal amount of the notes. O...
CERE - Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, annou...

CERE - Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, annou...

CERE - T2 Biosystems, Veru top healthcare gainers; Athenex, Invitae lead losers' pack

Gainers: T2 Biosystems ( TTOO ) +73% . Veru ( VERU ) +38% . Ginkgo Bioworks ( DNA ) +21% . Inotiv ( NOTV ) +20% . Accuray ( ARAY ) +17% . Losers: Athenex ( ATNX ) -46% . Invitae ( NVTA ) -43% . Cer...
CERE - Cerevel Therapeutics announces stock, convertible notes offering

Cerevel Therapeutics ( NASDAQ: CERE ) has launched an underwritten public offering of $250M of shares of its common stock. Terms of the offering are yet to be determined, Underwriters may be granted a 30-day option to purchase up to an additional $37.5M of common share...

CERE - Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, annou...

CERE - CinCor, Karuna top healthcare gainers; Reata, uniQure lead losers' pack

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...
Previous 10 Next 10